Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT04895410 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04895410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
January 17, 2022
Completion date
June 24, 2022
Enrollment
8 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma